Essentials in Lung Transplantation

Who and When to Transplant.- DCD vs DBD.- ECMO and EVLP.- Immunosuppression.- Acute Cellular Rejection.- Antibody Mediated Rejection.- The Human Respiratory Microbiome.- Community Acquired Respiratory Viruses.- Surveillance Bronchoscopy.- Chronic Lung Allograft Dysfunction:  Phenotypes and the future.- Lung Transplantation for Interstitial lung disease.- Lung Transplantation for Obstructive lung diseases.- Lung Transplantation for pulmonary hypertension.- Fungal Infection.- How to measure success. 

Professor Allan R Glanville, MBBS, MD, FRACP completed his training at Sydney University, Brompton Hospital, London, and Stanford University, California, USA. Prof Glanville is Medical Director of Lung Transplantation and Head of Service at the Department of Thoracic Medicine, St Vincent Hospital, Sydney, Australia. He is conjoint Professor of Medicine at UNSW and an editorial board member of the American Journal of Respiratory and Critical Care Medicine, the American Journal of Transplantation, the Journal of Heart and Lung Transplantation, and Seminars in Respiratory and Critical Care Medicine.
Currently President of the Thoracic Society of Australia and New Zealand, Prof Glanville is Past President of the International Society for Heart and Lung Transplantation and Programme Chair for the 2013 Annual Scientific Meeting in Montreal, Canada; Past Chair of the European and Australian Investigators in Lung Transplantation; and has authored over 200 publications including investigator driven global trials of immunosuppression and of novel therapies for RSV using small mRNAi. He is senior author of the 2015 International Consensus Guidelines for the Selection of Lung Transplantation Candidates, the joint ATS/ERS/JHLT BOS Guidelines, and the 2016 Pulmonary Antibody Mediated Rejection Consensus Report of the ISHLT. In Australia he is a foundation director of Outcomes Australia, a foundation member of ShareLife Australia, and a scientific advisor to Lymphangioleiomyomatosis Australia Research Alliance which complements work with international LAM groups and as a member of the Rare Lung Diseases Consortium.